Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …

BACKGROUND Somatic mutations accumulate in normal tissues as a function of time. The
great majority of these mutations have no effect on fitness, so selection does not act upon …

Circulating tumour DNA (ctDNA) assays conducted on plasma are rapidly developing a
strong evidence base for use in patients with cancer. The European Society for Medical …

Understanding the genetic and nongenetic determinants of tumor protein 53 (TP53)-
mutation-driven clonal evolution and subsequent transformation is a crucial step toward the …

Age-related change in human haematopoiesis causes reduced regenerative capacity,
cytopenias, immune dysfunction and increased risk of blood cancer,–, but the reason for …

Clonal hematopoiesis (CH), the clonal expansion of a blood stem cell and its progeny driven
by somatic driver mutations, affects over a third of people, yet remains poorly understood …

Acquired mutations are pervasive across normal tissues. However, understanding of the
processes that drive transformation of certain clones to cancer is limited. Here we study this …

Clonal expansions driven by somatic mutations become pervasive across human tissues
with age, including in the haematopoietic system, where the phenomenon is termed clonal …

Myeloid malignancies, including acute myeloid leukaemia (AML), arise from the expansion
of haematopoietic stem and progenitor cells that acquire somatic mutations. Bulk molecular …

The problem of resistance to therapy in cancer is multifaceted. Here we take a reductionist
approach to define and separate the key determinants of drug resistance, which include …